Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This phase 3 study is aimed to evaluate the safety and efficacy of YPEG-rhG-CSF in reducing
the infection manifested by febrile neutropenia in patients with non-myeloid malignancy who
receiving Myelosuppressive Chemotherapy which is likely to cause clinically significant
febrile neutropenia.
Phase:
Phase 3
Details
Lead Sponsor:
Xiamen Amoytop Biotech Co., Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences